Demonstration Formulary
6 Endocrine system
06-01-02-03 GLP1 agonists
| Dulaglutide Trulicity® |
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing
|
 How to use Trulicity Pen - Video NICE NG28: Type 2 diabetes in adults: management (Dec 2015) |
|
| Exenatide |
|
Formulary
|
|
|
NICE NG28: Type 2 diabetes in adults: management (Dec 2015) |
|
|
| Liraglutide Saxenda® |
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing • Injection The use of Liraglutide for this indication is restricted to prescribing in secondary care by a specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Saxenda ®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes
|
|
NICE TA664: Liraglutide for managing overweight and obesity NICE NG28: Type 2 diabetes in adults: management |
|
| Liraglutide Victoza® |
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing Use according to NICE guidance For the treatment of type 2 diabetes ONLY THIS IS FOR DIABETES ONLY. Prescribe by brand (Victoza®) to avoid patients inadvertently receiving a different product licensed for obesity. |
|
NICE TA664: Liraglutide for managing overweight and obesity How to use Victoza Pen - Video NICE NG28: Type 2 diabetes in adults: management (Dec 2015) |
|
|
| Semaglutide Rybelsus®▼ |
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing
Rybelsus is a tablet for once-daily oral use but has special administration directions:
|
|
|
| Semaglutide Wegovy® |
|
Formulary
|
PLEASE PRESCRIBE BY BRAND - NICE Guidance on prescribing Semaglutide is a biological medicine. Biological medicines must be prescribed and dispensed by brand name, see Biological medicines and Biosimilar medicines, under Guidance on Prescribing; manufacturer advises to record the brand name and batch number after each administration.
The use of semaglutide for this indication is restricted to prescribing by commissioned clinics in secondary care by a consultant led specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand (Wegovy®) to avoid patients inadvertently receiving a different product licensed for type 2 diabetes.
|
|
|
Links
- DVLA guidance
- How to use Trulicity Pen - Video
- How to use Victoza Pen - Video
- MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Alert: SGLT2 inhibitors: monitor ketones in blood during treatment interruption for surgical procedures or acute serious medical illness
- MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
- MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
- MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
- MHRA Alert: SGLT2 inhibitors: reports of Fourniers gangrene (necrotising fasciitis of the genitalia or perineum) (Feb 2019)
- MHRA Exenatide alert
- MHRA: Canagliflozin (Invokana, Vokanamet): signal of increased risk of lower extremity amputations observed in trial in high cardiovascular risk patients
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Dipeptidylpeptidase-4 inhibitors: risk of acute pancreatitis
- MHRA: Exenatide (Byetta ▼): risk of severe pancreatitis and renal failure
- MHRA: Insulin combined with pioglitazone: risk of cardiac failure
- MHRA: Insulin combined with pioglitazone: risk of cardiac failure
- MHRA: Pioglitazone: risk of bladder cancer
- MHRA: Pioglitazone: risk of bladder cancer
- MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
- MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
- MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
- MHRA: SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis
- MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
- MHRA: SGLT2 inhibitors: updated advice on increased risk of lower-limb amputation (mainly toes)
- NICE CG 28 Type 2 diabetes in adults: management NICE guideline
- NICE Guidance on prescribing
- NICE NG18: Diabetes (type 1 and type 2) in children and young people: diagnosis and management
- NICE NG19: Diabetic foot problems: prevention and management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG28: Type 2 diabetes in adults: management
- NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
- NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
- NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
- NICE NG28: Type 2 diabetes in adults: management (Dec 2015)
- NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
- NICE TA203: Diabetes (type 2) - liraglutide
- NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
- NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
- NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
- NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
- NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
- NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
- NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
- NICE TA572: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
- NICE TA583: Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
- NICE TA622: Sotagliflozin with insulin for treating type 1 diabetes
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA664: Liraglutide for managing overweight and obesity
- NICE TA679: Dapagliflozin for treating chronic heart failure with reduced ejection fraction
- NICE TA773: Empagliflozin for treating chronic heart failure with reduced ejection fraction
- NICE TA775: Dapagliflozin for treating chronic kidney disease
- TA63: Glitazones in the treatment of type 2 diabetes (Review of TA9 and TA21)